Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.

Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME.

JAMA Intern Med. 2020 Mar 9. doi: 10.1001/jamainternmed.2020.0193. [Epub ahead of print]

PMID:
32150237
2.

Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.

Rao T, Kiptanui Z, Dowell P, Triebwasser C, Alexander GC, Harris I.

JAMA Netw Open. 2020 Mar 2;3(3):e200274. doi: 10.1001/jamanetworkopen.2020.0274.

3.

Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.

Hsiue EH, Moore TJ, Alexander GC.

Clin Trials. 2020 Feb 29:1740774520907609. doi: 10.1177/1740774520907609. [Epub ahead of print]

PMID:
32114790
4.

A draft genome sequence of the elusive giant squid, Architeuthis dux.

da Fonseca RR, Couto A, Machado AM, Brejova B, Albertin CB, Silva F, Gardner P, Baril T, Hayward A, Campos A, Ribeiro ÂM, Barrio-Hernandez I, Hoving HJ, Tafur-Jimenez R, Chu C, Frazão B, Petersen B, Peñaloza F, Musacchia F, Alexander GC, Osório H, Winkelmann I, Simakov O, Rasmussen S, Rahman MZ, Pisani D, Vinther J, Jarvis E, Zhang G, Strugnell JM, Castro LFC, Fedrigo O, Patricio M, Li Q, Rocha S, Antunes A, Wu Y, Ma B, Sanges R, Vinar T, Blagoev B, Sicheritz-Ponten T, Nielsen R, Gilbert MTP.

Gigascience. 2020 Jan 1;9(1). pii: giz152. doi: 10.1093/gigascience/giz152.

5.

Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.

Heyward J, Olson L, Sharfstein JM, Stuart EA, Lurie P, Alexander GC.

JAMA Intern Med. 2019 Dec 30. doi: 10.1001/jamainternmed.2019.5459. [Epub ahead of print]

PMID:
31886822
6.

ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems.

Vermeulen LC, Swarthout MD, Alexander GC, Ginsburg DB, Pritchett KO, White SJ, Tryon J, Emmerich C, Nesbit TW, Greene W, Fox ER, Conti RM, Scott BE, Sheehy F, Melby MJ, Lantzy MA, Hoffman JM, Knoer S, Zellmer WA.

Am J Health Syst Pharm. 2020 Jan 8;77(2):84-112. doi: 10.1093/ajhp/zxz283. No abstract available.

PMID:
31803902
7.

Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.

Murimi-Worstell IB, Ballreich JM, Seamans MJ, Alexander GC.

PLoS One. 2019 Nov 12;14(11):e0225109. doi: 10.1371/journal.pone.0225109. eCollection 2019.

8.

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.

Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC.

Ann Rheum Dis. 2020 Feb;79(2):285-291. doi: 10.1136/annrheumdis-2019-216102. Epub 2019 Oct 31.

9.

Assessment of Pharmacy Closures in the United States From 2009 Through 2015.

Guadamuz JS, Alexander GC, Zenk SN, Qato DM.

JAMA Intern Med. 2019 Oct 21:1-3. doi: 10.1001/jamainternmed.2019.4588. [Epub ahead of print] No abstract available.

PMID:
31633745
10.

Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.

Qiao Y, Shin JI, Sang Y, Inker LA, Secora A, Luo S, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME.

Mayo Clin Proc. 2019 Nov;94(11):2220-2229. doi: 10.1016/j.mayocp.2019.05.031. Epub 2019 Oct 13.

PMID:
31619367
11.

Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR.

Novick TK, Surapaneni A, Shin JI, Alexander GC, Inker LA, Wright EA, Chang AR, Grams ME.

Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1581-1589. doi: 10.2215/CJN.00440119. Epub 2019 Oct 3.

PMID:
31582462
12.

Optimizing opioid prescribing and pain treatment for surgery: Review and conceptual framework.

Bicket MC, Brat GA, Hutfless S, Wu CL, Nesbit SA, Alexander GC.

Am J Health Syst Pharm. 2019 Sep 3;76(18):1403-1412. doi: 10.1093/ajhp/zxz146. Review.

PMID:
31505561
13.

Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder.

Chang HY, Daubresse M, Saloner B, Alexander GC.

Med Care. 2019 Sep;57(9):667-672. doi: 10.1097/MLR.0000000000001165.

PMID:
31404013
14.

Prescription drug monitoring programs: Assessing the association between "best practices" and opioid use in Medicare.

Moyo P, Simoni-Wastila L, Griffin BA, Harrington D, Alexander GC, Palumbo F, Onukwugha E.

Health Serv Res. 2019 Oct;54(5):1045-1054. doi: 10.1111/1475-6773.13197. Epub 2019 Aug 2.

PMID:
31372990
15.

Initial Opioid Prescriptions among U.S. Patients, 2012-2017.

Alexander GC, Kolodny A.

N Engl J Med. 2019 Jun 27;380(26):2587. doi: 10.1056/NEJMc1905100. No abstract available.

PMID:
31242377
16.

Clean indoor air laws, cigarette excise taxes, and smoking: Results from the current population survey-tobacco use supplement, 2003-2011.

Mojtabai R, Riehm KE, Cohen JE, Alexander GC, Rutkow L.

Prev Med. 2019 Sep;126:105744. doi: 10.1016/j.ypmed.2019.06.002. Epub 2019 Jun 4.

PMID:
31173803
17.

Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.

Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM.

JAMA Netw Open. 2019 Jun 5;2(6):e195388. doi: 10.1001/jamanetworkopen.2019.5388.

18.

Association of new opioid continuation with surgical specialty and type in the United States.

Bicket MC, Murimi IB, Mansour O, Wu CL, Alexander GC.

Am J Surg. 2019 Nov;218(5):818-827. doi: 10.1016/j.amjsurg.2019.04.010. Epub 2019 Apr 15.

PMID:
31023548
19.

Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older US Adults.

Qato DM, Alexander GC, Chakraborty A, Guadamuz JS, Jackson JW.

JAMA Netw Open. 2019 Apr 5;2(4):e192606. doi: 10.1001/jamanetworkopen.2019.2606.

20.

Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016.

Qiao Y, Alexander GC, Moore TJ.

Clin Trials. 2019 Jun;16(3):329-333. doi: 10.1177/1740774519839391. Epub 2019 Mar 29.

PMID:
30922113
21.

Reducing High-Dose Opioid Prescribing: State-Level Morphine Equivalent Daily Dose Policies, 2007-2017.

Heins SE, Frey KP, Alexander GC, Castillo RC.

Pain Med. 2020 Feb 1;21(2):308-316. doi: 10.1093/pm/pnz038.

PMID:
30865779
22.

Medicaid trends in prescription opioid and non-opioid use by HIV status.

Canan C, Alexander GC, Moore R, Murimi I, Chander G, Lau B.

Drug Alcohol Depend. 2019 Apr 1;197:141-148. doi: 10.1016/j.drugalcdep.2018.11.034. Epub 2019 Feb 13.

PMID:
30825794
23.

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.

Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC.

JAMA. 2019 Feb 19;321(7):676-685. doi: 10.1001/jama.2019.0235.

24.

Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.

Xu Y, Pilla SJ, Alexander GC, Murimi IB.

PLoS One. 2019 Feb 13;14(2):e0211820. doi: 10.1371/journal.pone.0211820. eCollection 2019.

25.

Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics.

Ogasawara K, Alexander GC.

Clin Pharmacol Drug Dev. 2019 Oct;8(7):914-921. doi: 10.1002/cpdd.658. Epub 2019 Feb 1.

PMID:
30707505
26.

Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults.

Pilla SJ, Segal JB, Alexander GC, Boyd CM, Maruthur NM.

J Am Geriatr Soc. 2019 May;67(5):1066-1073. doi: 10.1111/jgs.15790. Epub 2019 Jan 31.

27.

Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.

Heyward J, Jones CM, Compton WM, Lin DH, Losby JL, Murimi IB, Baldwin GT, Ballreich JM, Thomas DA, Bicket MC, Porter L, Tierce JC, Alexander GC.

JAMA Netw Open. 2018 Oct 5;1(6):e183044. doi: 10.1001/jamanetworkopen.2018.3044.

28.

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.

Saloner B, Levin J, Chang HY, Jones C, Alexander GC.

JAMA Netw Open. 2018 Aug 3;1(4):e181588. doi: 10.1001/jamanetworkopen.2018.1588.

29.

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.

Lin DH, Jones CM, Compton WM, Heyward J, Losby JL, Murimi IB, Baldwin GT, Ballreich JM, Thomas DA, Bicket M, Porter L, Tierce JC, Alexander GC.

JAMA Netw Open. 2018 Jun 1;1(2):e180235. doi: 10.1001/jamanetworkopen.2018.0235.

30.

Trends in Opioid Prescribing Among Hemodialysis Patients, 2007-2014.

Daubresse M, Alexander GC, Crews DC, Segev DL, McAdams-DeMarco MA.

Am J Nephrol. 2019;49(1):20-31. doi: 10.1159/000495353. Epub 2018 Dec 13.

31.

Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.

Alexander GC, Ogasawara K, Wiegand D, Lin D, Breder CD.

Ther Innov Regul Sci. 2019 Nov;53(6):752-758. doi: 10.1177/2168479018812058. Epub 2018 Dec 3.

PMID:
30509142
32.

Recent Progress in Vascular Tissue-Engineered Blood Vessels.

Chen J, Alexander GC, Bobba PS, Jun HW.

Adv Exp Med Biol. 2018;1064:123-144. doi: 10.1007/978-981-13-0445-3_8. Review.

PMID:
30471030
33.

A More Balanced Approach to Dietary Supplement Data-Reply.

Qato DM, Alexander GC, Lindau ST.

JAMA Pediatr. 2019 Jan 1;173(1):104-105. doi: 10.1001/jamapediatrics.2018.4032. No abstract available.

PMID:
30419136
34.

Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD.

Novick TK, Surapaneni A, Shin JI, Ballew SH, Alexander GC, Inker LA, Chang AR, Grams ME.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1886-1888. doi: 10.2215/CJN.08530718. Epub 2018 Nov 8. No abstract available.

35.

Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.

Moore TJ, Zhang H, Anderson G, Alexander GC.

JAMA Intern Med. 2018 Nov 1;178(11):1451-1457. doi: 10.1001/jamainternmed.2018.3931.

36.

Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users.

Murimi IB, Chang HY, Bicket M, Jones CM, Alexander GC.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):70-79. doi: 10.1002/pds.4639. Epub 2018 Sep 5.

PMID:
30187574
37.

Prescription Medication Use Among Children and Adolescents in the United States.

Qato DM, Alexander GC, Guadamuz JS, Lindau ST.

Pediatrics. 2018 Sep;142(3). pii: e20181042. doi: 10.1542/peds.2018-1042.

38.

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC.

JAMA Intern Med. 2018 Sep 1;178(9):1190-1198. doi: 10.1001/jamainternmed.2018.3034.

39.

Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults.

Secora A, Alexander GC, Ballew SH, Coresh J, Grams ME.

Drugs Aging. 2018 Aug;35(8):735-750. doi: 10.1007/s40266-018-0563-1.

40.

Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation.

Shin JI, Secora A, Alexander GC, Inker LA, Coresh J, Chang AR, Grams ME.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1144-1152. doi: 10.2215/CJN.13811217. Epub 2018 Jul 12.

41.

Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.

Saloner B, Stoller KB, Alexander GC.

N Engl J Med. 2018 Jul 5;379(1):4-6. doi: 10.1056/NEJMp1804059. No abstract available.

42.

Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.

Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW.

Pharmacotherapy. 2018 Sep;38(9):907-920. doi: 10.1002/phar.2158. Epub 2018 Jul 26.

43.

Prevalence of Dietary Supplement Use in US Children and Adolescents, 2003-2014.

Qato DM, Alexander GC, Guadamuz JS, Lindau ST.

JAMA Pediatr. 2018 Aug 1;172(8):780-782. doi: 10.1001/jamapediatrics.2018.1008. No abstract available.

44.

The Value of U.S. Pharmacopeial Standards: A Review of the Literature.

Heyward J, Padula W, Tierce JC, Alexander GC.

J Pharm Sci. 2018 Oct;107(10):2611-2617. doi: 10.1016/j.xphs.2018.06.004. Epub 2018 Jun 13. Review.

PMID:
29908148
45.

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.

Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Inker LA, Coresh J, Chang AR, Grams ME.

JAMA Intern Med. 2018 Jul 1;178(7):903-910. doi: 10.1001/jamainternmed.2018.0292.

46.

Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study.

Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC.

BMC Med. 2018 May 16;16(1):69. doi: 10.1186/s12916-018-1058-y.

47.

Clinical trial registration and reporting: a survey of academic organizations in the United States.

Mayo-Wilson E, Heyward J, Keyes A, Reynolds J, White S, Atri N, Alexander GC, Omar A, Ford DE; National Clinical Trials Registration and Results Reporting Taskforce Survey Subcommittee.

BMC Med. 2018 May 2;16(1):60. doi: 10.1186/s12916-018-1042-6.

48.

Opioid Oversupply After Joint and Spine Surgery: A Prospective Cohort Study.

Bicket MC, White E, Pronovost PJ, Wu CL, Yaster M, Alexander GC.

Anesth Analg. 2019 Feb;128(2):358-364. doi: 10.1213/ANE.0000000000003364.

PMID:
29677062
49.

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC.

PLoS One. 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018. Review.

50.

Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC.

Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):660-667. doi: 10.1002/pds.4437. Epub 2018 Apr 14.

Supplemental Content

Loading ...
Support Center